Skip to main content
OpenTrials
Completed

NCT Number: NCT03074149

Investigating Idiopathic Pulmonary Fibrosis in Greece

To gain further insight on the characteristics, management, disease progression and the outcomes of patients with IPF, as diagnosed and treated under real-world, clinical practice conditions in Greece. More specifically, this registry will be used to: Provide a comprehensive clinical picture of IPF, Track access to health care and cost of caring for IPF patients over time, Examine the implementation of treatment guidelines used on patients diagnosed with IPF, according to the existing diagnosis guidelines, Characterization of patients on different treatments. To provide information regarding survival and mortality causes, IPF exacerbations as well as IPF patient co-morbidities including myocardial infarction, CNS infarction, other arterial thromboembolic events, deep vein thrombosis, hemorrhage, gastrointestinal perforation and pulmonary hypertension. Data regarding IPF patient hospitalization will be collected and evaluated with regards to potential respiratory causes, and there will be documentation of treatment patterns and economic aspects. Patients will be followed up for 2 years and information regarding IPF treatment changes since the last visit will be collected.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Idiopathic Pulmonary Fibrosis Lung Diseases Lung Diseases, Interstitial Pulmonary Fibrosis Respiratory Tract Diseases

Age range

40 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Gen. Hosp. of Chest Diseases "Sotiria", Univ. Resp. Med., Athens, Greece

Loading trial locations.

About this study

Purpose: To gain further knowledge on the characteristics, management, progression and outcomes of patients with IPF as treated under real-world, clinical practice conditions in Greece

Study Design:

National, multi-center, observational disease registry based on new data from a significant sample size of IPF patients in Greece. Patients will be followed up for 2 years and information will be collected during this time period. This is a non-interventional study and primary data collected during study visits will be used

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Newly diagnosed (less than 6 months) or patients previously diagnosed with IPF (more than 6 months from baseline visit), based upon the consensus statement jointly issued by ATS/ERS/JRS/ALAT in 2011 (see Annexes 6 and 7 for HRCT and histological criteria in Annex 6)
  • Exclusion of other known causes of ILD (e.g., domestic and occupational environmental exposures, connective tissue disease, and drug toxicity)
  • Assessment of IPF based on HRCT or combinations of HRCT and surgical lung biopsy, if available
  • Age =40 years old at the time of inclusion
  • Written informed consent for participation in the registry
  • Patients that can be followed up further, during the scheduled study period

Exclusion criteria

  • Expected lung transplantation within the following 6 months
  • Participation in clinical trials

Treatment and study plan

Primary outcomes

  1. Number of Patients in Each Category of Non-pharmacological Treatment for Idiopathic Pulmonary Fibrosis (IPF) by Study Visit

    Time frame: At baseline visit and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit.

    Number in each category of non-pharmacological treatment (e.g. start of Long-term oxygen therapy (LTOT), new listing for lung transplantation, physiotherapy) for Idiopathic Pulmonary Fibrosis (IPF) by study visit is reported.

    The categories of non-pharmacological treatment for Idiopathic Pulmonary Fibrosis (IPF) are the following:

    • No
    • Yes
    • Unknown
    • Missing

  2. Number of Patients in Each Category of Physician's Clinical Assessment of the Probable Course of Idiopathic Pulmonary Fibrosis (IPF) by Study Visit

    Time frame: At baseline (up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit.

    Number of patients in each category of physician's clinical assessment of the probable course of IPF by study visit is reported. Physician's clinical rating of the probable course of IPF (stable, slow or rapid progression) was based on available Forced vital capacity (FVC) results, diffusion capacity for carbon monoxide (DLCO) results, physical examination, hospitalizations/events between the visits. The categories of physician's clinical assessment are the following:

    • Stable disease
    • Slow progression
    • Rapid progression
    • No judgement possible
    • Missing

  3. Number of Physician Contacts Per Patient by Study Visit

    Time frame: At baseline (up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit.

    Number of physician contacts per patient is reported. For the baseline visit mean and standard deviation of physician contacts with the patient up to 12 months prior to baseline visit is reported.

    For the study visits at 3 months, at 6 months, at 12 months, at 18 months and at 24 months mean and standard deviation of physician contacts with the patient since the last study visit is reported.

  4. Number of Visits in Outpatient Department by Study Visit

    Time frame: At baseline (up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit.

    Number of visits in outpatient department by study visit is reported. For the baseline visit mean and standard deviation of visits in outpatient department up to 12 months prior to baseline visit is reported.

    For the study visits at 3 months, at 6 months, at 12 months, at 18 months and at 24 months mean and standard deviation of visits in outpatient department since the last study visit is reported.

  5. Number of Visits in Pulmonologists by Study Visit

    Time frame: At baseline (up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit.

    Number of visits in pulmonologists by study visit is reported. For the baseline visit mean and standard deviation of visits in pulmonologists up to 12 months prior to baseline visit is reported.

    For the study visits at 3 months, at 6 months, at 12 months, at 18 months and at 24 months mean and standard deviation of visits in pulmonologists since the last study visit is reported.

  6. Number of Visits in Other Physicians Than the Pulmonologists by Study Visit

    Time frame: At baseline (up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit.

    Number of visits in other physicians than the pulmonologists by study visit is reported.

    For the baseline visit mean and standard deviation of visits in other physicians than the pulmonologists up to 12 months prior to baseline visit is reported.

    For the study visits at 3 months, at 6 months, at 12 months, at 18 months and at 24 months mean and standard deviation of visits in other physicians than the pulmonologists since the last study visit is reported.

  7. Number of Idiopathic Pulmonary Fibrosis (IPF) Related Procedures by Study Visit

    Time frame: At baseline (up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit.

    Number of Idiopathic Pulmonary Fibrosis (IPF) related procedures by study visit is reported.

    For the baseline visit mean and standard deviation of Idiopathic Pulmonary Fibrosis (IPF) related procedures up to 12 months prior to baseline visit is reported.

    For the study visits at 3 months, at 6 months, at 12 months, at 18 months and at 24 months mean and standard deviation of Idiopathic Pulmonary Fibrosis (IPF) related procedures since the last study visit is reported.

  8. Number of Patients in Each Category of Hospitalizations by Study Visit

    Time frame: At baseline up to 12 months prior to baseline visit) and at 3 months, at 6 months, at 12 months, at 18 months and at 24 months after the baseline visit.

    Number of patients in each category of hospitalizations by study visit is reported.

    For the baseline visit number of patients in each category of hospitalizations up to 12 months prior to baseline visit is reported.

    For the study visits at 3 months, at 6 months, at 12 months, at 18 months and at 24 months number of patients in each category of hospitalizations since the last study visit is reported.

    The categories of hospitalization were:

    • No
    • Yes
    • Unknown
    • Missing

  9. Number of Patients in Each Category With Usage of Pirfenidone and Nintedanib

    Time frame: From signing the informed consent onwards until the end of the study, up to 24 months.

    Number of patients in each category with usage of pirfenidone and nintedanib is reported.

    The categories for usage of pirfenidone and nintedanib are the following:

    • Yes
    • No
    • Unknown
    • Missing

Secondary outcomes

  1. Number of Patients in Each Category of Concomitant Medications

    Time frame: From signing the informed consent onwards until the end of the study, up to 24 months.

    Concomitant medication was defined as any treatment presented following the Informed Consent Form (ICF) signature. If stop date was missing in the electronic Case Report Form (eCRF), medication was considered as concomitant. The number of patients in each category of the following concomitant medications is reported. The concomitant medications are:

    • Corticosteroids
    • N-Acetylcysteine
    • Azathioprine
    • Cyclophosphamide
    • Cyclosporine A
    • Other immuno-suppressant
    • Anticoagulants
    • Gastroesophageal reflux disease (GERD) medication
    • Phosphodiesterase type 5 (PDE-5) inhibitor
    • Endothelin receptor antagonist
    • Non-steroidal anti-inflammatory drugs (NSAIDs) other than aspirin
    • Hormonal contraceptives
    • Hormone replacement therapy
    • Anti-vascular endothelial growth factor (VEGF) drugs
    • Other (other than listed above)

    The categories for each concomitant medication listed above are the following:

    • Yes
    • No
    • Unknown
    • Missing

Sponsors and collaborators

Lead sponsor

Boehringer Ingelheim

Industry

Registry information

Acronym: INDULGEIPF

Important dates

Study start
2017
Primary completion
2021
Study completion
2021
First posted
Mar 8, 2017
Registry last updated
Oct 5, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.